Charles River Laboratories Intl. Inc (NYSE:CRL) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC lessened its stake in shares of Charles River Laboratories Intl. Inc (NYSE:CRL) by 67.6% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 6,692 shares of the medical research company’s stock after selling 13,984 shares during the quarter. SG Americas Securities LLC’s holdings in Charles River Laboratories Intl. were worth $723,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the stock. Hood River Capital Management LLC increased its position in Charles River Laboratories Intl. by 2.2% during the third quarter. Hood River Capital Management LLC now owns 269,587 shares of the medical research company’s stock worth $29,121,000 after acquiring an additional 5,770 shares during the period. Advisors Asset Management Inc. grew its holdings in shares of Charles River Laboratories Intl. by 3,445.5% during the 3rd quarter. Advisors Asset Management Inc. now owns 11,452 shares of the medical research company’s stock valued at $1,237,000 after purchasing an additional 11,129 shares during the last quarter. Putnam FL Investment Management Co. bought a new stake in shares of Charles River Laboratories Intl. during the 3rd quarter valued at approximately $13,181,000. Russell Investments Group Ltd. boosted its position in Charles River Laboratories Intl. by 181.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 129,206 shares of the medical research company’s stock worth $13,957,000 after buying an additional 83,324 shares during the period. Finally, HighPoint Advisor Group LLC boosted its position in Charles River Laboratories Intl. by 48.8% during the 3rd quarter. HighPoint Advisor Group LLC now owns 8,056 shares of the medical research company’s stock worth $944,000 after buying an additional 2,643 shares during the period. 95.80% of the stock is currently owned by institutional investors and hedge funds.

Shares of Charles River Laboratories Intl. Inc (NYSE CRL) traded down $0.29 during midday trading on Friday, reaching $109.45. 195,284 shares of the company’s stock were exchanged, compared to its average volume of 287,575. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.88 and a quick ratio of 1.62. Charles River Laboratories Intl. Inc has a twelve month low of $75.25 and a twelve month high of $119.05. The company has a market capitalization of $5,197.45, a PE ratio of 26.70, a P/E/G ratio of 1.75 and a beta of 0.89.

Charles River Laboratories Intl. (NYSE:CRL) last issued its earnings results on Thursday, November 9th. The medical research company reported $1.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.22 by $0.08. Charles River Laboratories Intl. had a net margin of 10.72% and a return on equity of 26.58%. The firm had revenue of $464.23 million for the quarter, compared to analysts’ expectations of $458.93 million. During the same quarter last year, the business earned $1.18 earnings per share. The business’s revenue was up 9.0% on a year-over-year basis. sell-side analysts forecast that Charles River Laboratories Intl. Inc will post 5.14 earnings per share for the current year.

CRL has been the topic of several recent research reports. Credit Suisse Group reiterated a “neutral” rating and set a $112.00 target price (up from $95.00) on shares of Charles River Laboratories Intl. in a research report on Monday, October 16th. Zacks Investment Research upgraded shares of Charles River Laboratories Intl. from a “hold” rating to a “buy” rating and set a $129.00 target price on the stock in a research report on Tuesday, October 24th. ValuEngine downgraded shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research report on Friday, November 10th. Jefferies Group reiterated a “buy” rating and set a $120.00 target price on shares of Charles River Laboratories Intl. in a research report on Tuesday, September 12th. Finally, SunTrust Banks restated a “buy” rating and set a $113.00 price target on shares of Charles River Laboratories Intl. in a research note on Friday, November 17th. Six research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $110.21.

In related news, insider Davide Molho sold 6,165 shares of the firm’s stock in a transaction on Thursday, October 5th. The stock was sold at an average price of $110.00, for a total value of $678,150.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Bradley Nixon Scharfe sold 1,000,000 shares of the firm’s stock in a transaction on Friday, November 10th. The stock was sold at an average price of $0.27, for a total value of $270,000.00. In the last ninety days, insiders purchased 10,500 shares of company stock valued at $2,885 and sold 1,056,776 shares valued at $2,011,952. Company insiders own 2.20% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was posted by Week Herald and is owned by of Week Herald. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://weekherald.com/2017/12/30/charles-river-laboratories-international-inc-crl-stake-lessened-by-sg-americas-securities-llc.html.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply